Alana McNulty
Director/Board Member chez JANUX THERAPEUTICS, INC.
Fortune : - $ au 31/03/2024
Profil
Alana B.
McNulty is an Independent Director at Janux Therapeutics, Inc. and Chief Business Officer at eFFECTOR Therapeutics Operations, Inc. She previously served as an Independent Director at NKGen Biotech, Inc. and General Manager & Head-Corporate Development at Advanced Tissue Sciences, Inc. Alana also held positions at The Bear Stearns Cos., Inc., Elitra Pharmaceuticals, Inc., BrainCells, Inc., Lumena Pharmaceuticals, Inc., and Excaliard Pharmaceuticals, Inc. She has a background in finance and business development.
Alana completed her undergraduate studies at the University of California, Santa Barbara and holds an MBA from UCLA Anderson School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
JANUX THERAPEUTICS, INC.
-.--% | 14/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Alana McNulty
| Sociétés | Poste | Début |
|---|---|---|
| JANUX THERAPEUTICS, INC. | Director/Board Member | 07/09/2021 |
eFFECTOR Therapeutics Operations, Inc.
 eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 07/01/2021 |
Anciens postes connus de Alana McNulty
| Sociétés | Poste | Fin |
|---|---|---|
| EFFECTOR THERAPEUTICS, INC. | Director of Finance/CFO | 01/12/2020 |
Lumena Pharmaceuticals, Inc.
 Lumena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lumena Pharmaceuticals, Inc. developed oral therapeutics for rare liver diseases. The firm was engaged in the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, such as nonalcoholic steatohepatitis. The company was founded by Bronislava Gedulin and Michael G. Grey in January 2011 and was headquartered in San Diego, CA. | Director of Finance/CFO | 01/11/2014 |
Excaliard Pharmaceuticals, Inc.
 Excaliard Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Excaliard Pharmaceuticals, Inc. manufactures, develops therapeutics for the treatment of scarring and fibrotic disorders. The company was founded by John Gordon Foulkes and Nicholas M. Dean in 2006 and is headquartered in New York, NY. | Director of Finance/CFO | 01/11/2011 |
BrainCells, Inc.
 BrainCells, Inc. Pharmaceuticals: MajorHealth Technology BrainCells Inc. discovers and develops drugs. The company was founded by Fred H. Gage and Harry F. Hixson, Jr. in 2003 and is headquartered in San Diego, CA. | Director of Finance/CFO | 01/01/2011 |
Formation de Alana McNulty
| University of California, Santa Barbara | Undergraduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| JANUX THERAPEUTICS, INC. | Health Technology |
| EFFECTOR THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
| Advanced Tissue Sciences, Inc. | Commercial Services |
The Bear Stearns Cos., Inc.
 The Bear Stearns Cos., Inc. Investment Banks/BrokersFinance Bear Stearns Cos., Inc. provides investment banking, securities trading and brokerage services. Their clients include corporations, institutions, governments and individuals. They are engaged in segments that encompass capital markets, wealth management and global clearing services. The company was founded in 1923 and is headquartered in New York, NY. | Finance |
Elitra Pharmaceuticals, Inc.
 Elitra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Elitra Pharmaceuticals, Inc. used to develop pharmaceutical products. The company employed proprietary methods for gene analysis and anti-microbial drug discovery. It used to develop technology to miniaturize anti-microbial drug screens. It was also engaged in the identification, development and commercialization of novel antimicrobial compounds that target essential gene products of pathogenic organisms. The company was founded in 1997 and was headquartered in San Diego, CA | Health Technology |
BrainCells, Inc.
BrainCells, Inc. Pharmaceuticals: MajorHealth Technology BrainCells Inc. discovers and develops drugs. The company was founded by Fred H. Gage and Harry F. Hixson, Jr. in 2003 and is headquartered in San Diego, CA. | Health Technology |
Lumena Pharmaceuticals, Inc.
Lumena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lumena Pharmaceuticals, Inc. developed oral therapeutics for rare liver diseases. The firm was engaged in the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, such as nonalcoholic steatohepatitis. The company was founded by Bronislava Gedulin and Michael G. Grey in January 2011 and was headquartered in San Diego, CA. | Health Technology |
Excaliard Pharmaceuticals, Inc.
Excaliard Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Excaliard Pharmaceuticals, Inc. manufactures, develops therapeutics for the treatment of scarring and fibrotic disorders. The company was founded by John Gordon Foulkes and Nicholas M. Dean in 2006 and is headquartered in New York, NY. | Health Technology |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Commercial Services |
